ImmuPharma reports an operating loss of £3.2 million for the six months to the end of June compared with £1.5 million last time. Research and development expenditure in the period was £2.5 million (£0.87 million for the six months ended 30 June 2015) reflecting primarily the significantly increased expenditure related to the Lupuzor Phase III clinical trial. Administrative expenses were £733,893 during the Period (£677,111 for the six months ended 30 June 2015). Consistent with the reclassification of expenses between research and development and administration undertaken for the accounts for the year ended 31 December 2015, the expenses for the 6 months ended 30 June 2015 have also been reclassified to aid comparability.
+0.51p (+1.31%)delayed 18:15PM